These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 34394248)

  • 1. BRAF
    Kaabouch M; Chahdi H; Azouzi N; Oukabli M; Rharrassi I; Boudhas A; Jaddi H; Ababou M; Dakka N; Boichard A; Bakri Y; Dupuy C; Al Bouzidi A; El Hassani RA
    Afr Health Sci; 2020 Dec; 20(4):1849-1856. PubMed ID: 34394248
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detection of BRAFV600E mutation on fine needle aspiration specimens of thyroid nodule refines cyto-pathology diagnosis, especially in BRAF600E mutation-prevalent area.
    Chung KW; Yang SK; Lee GK; Kim EY; Kwon S; Lee SH; Park DJ; Lee HS; Cho BY; Lee ES; Kim SW
    Clin Endocrinol (Oxf); 2006 Nov; 65(5):660-6. PubMed ID: 17054470
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Follicular histotypes of oncocytic thyroid carcinomas do not carry mutations of the BRAF hot-spot.
    Musholt PB; Musholt TJ; Morgenstern SC; Worm K; Sheu SY; Schmid KW
    World J Surg; 2008 May; 32(5):722-8. PubMed ID: 18235983
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BRAF V600E mutation in papillary thyroid carcinoma: significant association with node metastases and extra thyroidal invasion.
    Chakraborty A; Narkar A; Mukhopadhyaya R; Kane S; D'Cruz A; Rajan MG
    Endocr Pathol; 2012 Jun; 23(2):83-93. PubMed ID: 22105775
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic Significance of TERT Promoter Mutations in Papillary Thyroid Carcinomas in a BRAF(V600E) Mutation-Prevalent Population.
    Lee SE; Hwang TS; Choi YL; Han HS; Kim WS; Jang MH; Kim SK; Yang JH
    Thyroid; 2016 Jul; 26(7):901-10. PubMed ID: 27184112
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increase in Papillary Thyroid Cancer Incidence Is Accompanied by Changes in the Frequency of the BRAF V600E Mutation: A Single-Institution Study.
    Kowalska A; Walczyk A; Kowalik A; Pałyga I; Trybek T; Kopczyński J; Kajor M; Chrapek M; Pięciak L; Chłopek M; Góźdź S; Kamiński G
    Thyroid; 2016 Apr; 26(4):543-51. PubMed ID: 26889698
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Expression of BRAF V600E mutation in different thyroid lesions].
    Wang W; Li XH; Zhang YH; Li J; Chen J; Zhao P; Li QY; Xiang JJ; Li X; Xu RJ
    Zhonghua Zhong Liu Za Zhi; 2011 May; 33(5):354-7. PubMed ID: 21875464
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BRAF overexpression is associated with BRAF V600E mutation in papillary thyroid carcinomas.
    da Silva RC; de Paula HS; Leal CB; Cunha BC; de Paula EC; Alencar RC; Meneghini AJ; Silva AM; Gontijo AP; Wastowski IJ; Saddi VA
    Genet Mol Res; 2015 May; 14(2):5065-75. PubMed ID: 26125698
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The relationship of the BRAF(V600E) mutation and the established prognostic factors in papillary thyroid carcinomas.
    Kurt B; Yalçın S; Alagöz E; Karslıoğlu Y; Yigit N; Günal A; Deveci MS
    Endocr Pathol; 2012 Sep; 23(3):135-40. PubMed ID: 22767446
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of BRAFV600E mutation with clinicopathological features of papillary thyroid carcinoma: a study on a Chinese population.
    Liu S; Zhang B; Zhao Y; Chen P; Ji M; Hou P; Shi B
    Int J Clin Exp Pathol; 2014; 7(10):6922-8. PubMed ID: 25400776
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Uncommon BRAF mutations in the follicular variant of thyroid papillary carcinoma: New insights.
    Rossi ED; Martini M; Bizzarro T; Capodimonti S; Cenci T; Lombardi CP; Pontecorvi A; Fadda G; Larocca LM
    Cancer Cytopathol; 2015 Oct; 123(10):593-602. PubMed ID: 26230187
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical utility of TERT promoter mutations and ALK rearrangement in thyroid cancer patients with a high prevalence of the BRAF V600E mutation.
    Bae JS; Kim Y; Jeon S; Kim SH; Kim TJ; Lee S; Kim MH; Lim DJ; Lee YS; Jung CK
    Diagn Pathol; 2016 Feb; 11():21. PubMed ID: 26857243
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Type and prevalence of BRAF mutations are closely associated with papillary thyroid carcinoma histotype and patients' age but not with tumour aggressiveness.
    Trovisco V; Soares P; Preto A; de Castro IV; Lima J; Castro P; Máximo V; Botelho T; Moreira S; Meireles AM; Magalhães J; Abrosimov A; Cameselle-Teijeiro J; Sobrinho-Simões M
    Virchows Arch; 2005 Jun; 446(6):589-95. PubMed ID: 15902486
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of plasma BRAF(V600E) mutation is associated with lung metastasis in papillary thyroid carcinomas.
    Kim BH; Kim IJ; Lee BJ; Lee JC; Kim IS; Kim SJ; Kim WJ; Jeon YK; Kim SS; Kim YK
    Yonsei Med J; 2015 May; 56(3):634-40. PubMed ID: 25837167
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TERT promoter mutations and their association with BRAF V600E mutation and aggressive clinicopathological characteristics of thyroid cancer.
    Liu X; Qu S; Liu R; Sheng C; Shi X; Zhu G; Murugan AK; Guan H; Yu H; Wang Y; Sun H; Shan Z; Teng W; Xing M
    J Clin Endocrinol Metab; 2014 Jun; 99(6):E1130-6. PubMed ID: 24617711
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of BRAF V600E mutation as a potential marker for prognostic stratification of papillary thyroid carcinoma: a long-term follow-up study.
    Daliri M; Abbaszadegan MR; Bahar MM; Arabi A; Yadollahi M; Ghafari A; Taghehchian N; Zakavi SR
    Endocr Res; 2014; 39(4):189-93. PubMed ID: 24679337
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BRAFV600E mutation in fine-needle aspiration aspirates: Association with poorer prognostic factors in larger papillary thyroid carcinomas.
    Lee JI; Jang HW; Kim SW; Kim JW; Oh YL; Chung JH
    Head Neck; 2013 Apr; 35(4):548-53. PubMed ID: 22488961
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence of
    Kim H; Kim BH; Kim YK; Kim JM; Oh SY; Kim EH; Lee MJ; Kim JH; Jeon YK; Kim SS; Lee BJ; Kim YK; Kim IJ
    J Korean Med Sci; 2018 Jul; 33(27):e75. PubMed ID: 29962924
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer.
    Xing M; Alzahrani AS; Carson KA; Viola D; Elisei R; Bendlova B; Yip L; Mian C; Vianello F; Tuttle RM; Robenshtok E; Fagin JA; Puxeddu E; Fugazzola L; Czarniecka A; Jarzab B; O'Neill CJ; Sywak MS; Lam AK; Riesco-Eizaguirre G; Santisteban P; Nakayama H; Tufano RP; Pai SI; Zeiger MA; Westra WH; Clark DP; Clifton-Bligh R; Sidransky D; Ladenson PW; Sykorova V
    JAMA; 2013 Apr; 309(14):1493-501. PubMed ID: 23571588
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinicopathologic features and BRAF(V600E) mutation analysis in cutaneous metastases from well-differentiated thyroid carcinomas.
    Erickson LA; Jin L; Nakamura N; Bridges AG; Markovic SN; Lloyd RV
    Cancer; 2007 May; 109(10):1965-71. PubMed ID: 17387744
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.